How CRISPR-Cas9 Edits Genes with Molecular Precision

A Bacterial Immune System Repurposed to Rewrite the Human Genome

In 1987, Japanese researcher Yoshizumi Ishino noticed repeating DNA sequences in E. coli that he could not explain. Twenty-five years later, those sequences — CRISPR, Clustered Regularly Interspaced Short Palindromic Repeats — turned out to be a bacterial immune memory system that stores fragments of viral DNA to recognise and destroy future infections. In 2012, Jennifer Doudna and Emmanuelle Charpentier demonstrated that the Cas9 protein from this system could be programmed with a short RNA guide to cut any target DNA sequence with molecular precision. The 2020 Nobel Prize in Chemistry followed. CRISPR-Cas9 has become the most widely used genome editing tool in the history of biology.

CRISPR-Cas9 can delete genes, correct disease-causing mutations, insert new sequences, and regulate gene activity — in cells, organisms, and now human patients. The pace of applications has been extraordinary: from laboratory discovery to approved human therapy in under a decade.

How CRISPR-Cas9 Works

The system requires two components: the Cas9 protein (a molecular scissors) and a single guide RNA (sgRNA) that directs Cas9 to the target sequence.

• The guide RNA is approximately 100 nucleotides long. The first 20 nucleotides (the spacer sequence) are complementary to the target DNA sequence chosen by the researcher.
• Cas9 scans DNA, pausing wherever it encounters a short motif called the PAM (protospacer adjacent motif) — typically NGG for the commonly used S. pyogenes Cas9.
• When the guide RNA matches the adjacent DNA sequence, Cas9 undergoes a conformational change and makes a double-strand break: both strands of the DNA helix are cut.
• The cell attempts to repair the break using one of two main pathways: non-homologous end joining (NHEJ), which is error-prone and often introduces small insertions or deletions (indels) that disrupt gene function; or homology-directed repair (HDR), which uses a provided template to make precise edits.

Delivery into Cells

Getting CRISPR components into target cells is a central challenge. Several delivery methods are in use.

• Viral vectors — particularly adeno-associated viruses (AAV) — package and deliver the CRISPR machinery into cells with high efficiency. Different AAV serotypes target different tissues; AAV9 targets the central nervous system, AAV8 targets the liver.
• Lipid nanoparticles (LNPs) — the same technology used in mRNA COVID-19 vaccines — encapsulate CRISPR RNA components and fuse with cell membranes, releasing the cargo. LNPs delivered Cas9 mRNA and guide RNA to liver cells in the first approved CRISPR therapeutic.
• Ribonucleoprotein complexes (RNPs) package pre-assembled Cas9 protein and guide RNA, reducing off-target activity and persistence time in the cell compared to DNA-based delivery.
• Electroporation uses electric pulses to create transient pores in cell membranes, allowing entry of CRISPR components — widely used for ex vivo editing of patient cells.

Medical Applications

The first CRISPR therapy approved by the US FDA, Casgevy (exa-cel, developed by Vertex Pharmaceuticals and CRISPR Therapeutics), received approval in December 2023 for sickle cell disease and transfusion-dependent beta-thalassaemia. It works by editing a patient's own haematopoietic stem cells to reactivate fetal haemoglobin production — reactivating a gene normally silenced after birth — compensating for the defective adult haemoglobin.

Next-Generation Editing Tools

Cas9 creates double-strand breaks, which can cause unintended effects. Newer tools improve precision.

• Base editing, developed by David Liu's lab, uses a catalytically impaired Cas9 (nickase) fused to a deaminase enzyme to convert one DNA base to another without cutting both strands. Adenine base editors (ABEs) convert A·T to G·C; cytosine base editors (CBEs) convert C·G to T·A. They can correct the four most common point mutation types without double-strand breaks.
• Prime editing, also from Liu's lab (2019), uses a Cas9 nickase fused to a reverse transcriptase and a prime editing guide RNA (pegRNA) to write new genetic information directly into a specific site. It can make all 12 types of point mutations, small insertions, and small deletions with low off-target effects.
• CRISPR-Cas12a (Cpf1) recognises T-rich PAM sequences and makes staggered cuts, offering an alternative targeting range.

Off-Target Effects and Safety

Off-target editing — cuts at unintended genomic sites where the guide RNA matches imperfectly — is the primary safety concern. High-fidelity Cas9 variants (eSpCas9, HiFi Cas9) with reduced non-specific binding substantially lower off-target rates. Whole-genome sequencing of edited cells before therapeutic use allows comprehensive safety assessment. In the Casgevy trials, no concerning off-target events were detected after two years of follow-up in treated patients, providing early validation that CRISPR therapies can achieve the specificity required for clinical use.